AVITA Medical, Inc. (RCEL) Misses Q1 EPS by 21c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Cantor Fitzgerald Says Buy Avita Medical Ltd. (RCEL) on Weakness Following Q1 Results
May 9, 2025 10:13 AM EDTCantor Fitzgerald analyst Ross Osborne reiterated an Overweight rating and $19.00 price target on Avita Medical Ltd. (NASDAQ: RCEL) following Q1 results, saying they would buy on today's weakness. The stock is down 22% in early trading.
The analyst commented, "We reiterate our Overweight rating and... More
